Trademark: 88167507
Word
TANNQUILYNNE
Status
Registered
Status Code
700
Status Date
Tuesday, May 18, 2021
Serial Number
88167507
Registration Number
6351061
Registration Date
Tuesday, May 18, 2021
Mark Type
4000
Filing Date
Wednesday, October 24, 2018
Published for Opposition
Tuesday, March 2, 2021

Trademark Owner History
SyneuRx International (Taiwan) Corp. - Original Registrant

Classifications
5 Syrups for pharmaceutical purposes for the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Pharmaceutical preparations for the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Pharmaceutical preparations for the treatment and prevention of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Transdermal patches for use in the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes; Natural dietary supplements for the treatment of Hyperglycemia, diabetes, prediabetes, insulin resistance, diabetic ketoacidosis (DKA), hyperglycemic hyperosmolar nonketotic syndrome (HHNS), Hyperthyroidism, Polyphagia, polydipsia, polyuria, glycosuria, increased thirst and a frequent need to Urinate, coma, abdominal pain, poor wound healing, Stomach and intestinal problems such as chronic constipation or diarrhea, Worse vision, Damage to eyes, blood vessels, or kidneys, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, hypertension, heart disease, heart attack, stroke, thrombosis, fatty liver, liver cirrhosis, hyperuricemia, gout, pain in joints, joint stiffness, redness and swelling, Autism, Asperger's disorder, panic disorder, post-traumatic stress disorder, pain, childhood learning disorder, attention deficit hyperactivity disorder (ADHD), Tourette's syndrome, mania, obsessive compulsive disorder, and other diseases or symptoms related to CNS disorder, metabolic disorder, or diabetes

Trademark Events
May 18, 2021
Registered-Principal Register
Mar 2, 2021
Official Gazette Publication Confirmation E-Mailed
Mar 2, 2021
Published For Opposition
Feb 10, 2021
Notification Of Notice Of Publication E-Mailed
Dec 31, 2020
Case Returned To Examination
Dec 31, 2020
Notice Of Allowance Cancelled
Oct 29, 2020
Notice Of Approval Of Extension Request E-Mailed
Oct 28, 2020
Attorney Review/Decision On Amendment Required
Oct 28, 2020
Petition To Director - Change Basis - Granted
Oct 28, 2020
Extension 3 Granted
Sep 10, 2020
Extension 3 Filed
Oct 18, 2020
Assigned To Petition Staff
Sep 18, 2020
Case Assigned To Intent To Use Paralegal
Sep 10, 2020
Teas Extension Received
Sep 10, 2020
Teas Petition To Amend Basis Received
Jul 24, 2020
Applicant/Correspondence Changes (Non-Responsive) Entered
Jul 24, 2020
Teas Change Of Correspondence Received
Jul 24, 2020
Teas Change Of Domestic Representatives Address
Jul 24, 2020
Attorney/Dom.Rep.Revoked And/Or Appointed
Jul 24, 2020
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Jul 24, 2020
Teas Change Of Owner Address Received
Feb 29, 2020
Notice Of Approval Of Extension Request E-Mailed
Feb 27, 2020
Extension 2 Granted
Feb 27, 2020
Extension 2 Filed
Feb 27, 2020
Teas Extension Received
Aug 15, 2019
Notice Of Approval Of Extension Request E-Mailed
Aug 13, 2019
Extension 1 Granted
Aug 13, 2019
Extension 1 Filed
Aug 13, 2019
Teas Extension Received
Mar 12, 2019
Noa E-Mailed - Sou Required From Applicant
Jan 15, 2019
Official Gazette Publication Confirmation E-Mailed
Jan 15, 2019
Published For Opposition
Dec 26, 2018
Notification Of Notice Of Publication E-Mailed
Dec 7, 2018
Approved For Pub - Principal Register
Dec 7, 2018
Assigned To Examiner
Nov 6, 2018
New Application Office Supplied Data Entered In Tram
Oct 27, 2018
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24